Strides and Incepta Partner to Expand Women’s Health Access with WHO-Prequalified Contraceptive

Strides Pharma Science Limited has partnered with Incepta Pharmaceuticals to market the world’s first WHO-prequalified generic version of subcutaneous depot medroxyprogesterone acetate (DMPA-SC) in Africa. This partnership aims to strengthen women’s access to affordable, quality reproductive health solutions, diversifying the supply of DMPA-SC and helping health systems procure at more affordable prices. The WHO prequalification of this three-month contraceptive, which can be administered by healthcare workers or self-injected after appropriate training, is a significant step toward meeting the unmet need of over 250 million women worldwide who still lack access to modern contraception.